CD274 and non-small cell lung carcinoma: Several previously published meta-analyses have analyzed the efficacy and toxicity of anti-PD-1/PD-L1 antibodies [6, 10, 11], but none of them compared anti-PD-1/PD-L1 antibodies with the second-line chemotherapy, docetaxel, for pretreated advanced NSCLC patients.